Evaluation of treatment response in active tuberculosis using QuantiFERON-TB Gold Plus.

IF 2.2 4区 医学 Q4 BIOCHEMISTRY & MOLECULAR BIOLOGY
Setareh Mamishi, Majid Marjani, Babak Pourakbari, Reihaneh Hosseinpour Sadeghi, Shima Mahmoudi
{"title":"Evaluation of treatment response in active tuberculosis using QuantiFERON-TB Gold Plus.","authors":"Setareh Mamishi,&nbsp;Majid Marjani,&nbsp;Babak Pourakbari,&nbsp;Reihaneh Hosseinpour Sadeghi,&nbsp;Shima Mahmoudi","doi":"10.1684/ecn.2020.0457","DOIUrl":null,"url":null,"abstract":"<p><p>Tuberculosis (TB) is one of the leading infectious causes of death worldwide and despite the progress recently made in TB control at a global level, the decline in its incidence is still slow. It is therefore crucial to evaluate the performance of new tools for monitoring of TB treatment. The aim of this study was to evaluate the response to tuberculosis treatment using the QuantiFERON-TB Gold Plus (QFT-Plus) kit. Blood samples of 100 patients with active TB were taken before treatment and after three months, if treatment was successful and sputum culture was negative. Whole blood was incubated in the presence or absence of the TB antigens, TB1 and TB2-specific antigens, and the production of IFN-γ was determined using the QuantiFERON-TB Gold Plus (QFT-Plus) test. The data were analyzed using SPSS 16 software and statistical significance was assessed at a two-tailed P value of 0.05. The median values of IFN-γ released following stimulation with TB1 peptides decreased slightly after treatment (2.5 IU/mL (IQR: 0.9-5.3), compared to the baseline (3.4 IU/mL (IQR: 0.5-6.6)). Also, with respect to the TB1 antigen, 38 out of 45 patients were positive for the QFT test before treatment (84.4%) and 37 cases after treatment (82.2%). On the other hand, the median values of IFN-γ determined with the TB2 test declined marginally after treatment (2.7 IU/mL; IQR: 0.95-5.8), as compared to pretreatment (3.0 IU/mL; IQR: 0.7-8.9). Thirty-nine out of 45 patients (86.7%) before initiation of treatment and 37 cases following a 3-month treatment (82.2%) were had positive values. Moreover, the median values of IFN-γ of TB2 minus TB1 before and after treatment were 0.17 (IQR: 0-1.0) and 0.03 (IQR: 0.0.48), respectively; however, these differences were not significant (p value=0.29). Conclusion: The results of this study show no significant differences between the IFN-γ release in TB patients prior to and after treatment. However, more extensive studies are needed in different populations with higher sample sizes to validate these results.</p>","PeriodicalId":11749,"journal":{"name":"European cytokine network","volume":"31 4","pages":"129-133"},"PeriodicalIF":2.2000,"publicationDate":"2020-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European cytokine network","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1684/ecn.2020.0457","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}
引用次数: 1

Abstract

Tuberculosis (TB) is one of the leading infectious causes of death worldwide and despite the progress recently made in TB control at a global level, the decline in its incidence is still slow. It is therefore crucial to evaluate the performance of new tools for monitoring of TB treatment. The aim of this study was to evaluate the response to tuberculosis treatment using the QuantiFERON-TB Gold Plus (QFT-Plus) kit. Blood samples of 100 patients with active TB were taken before treatment and after three months, if treatment was successful and sputum culture was negative. Whole blood was incubated in the presence or absence of the TB antigens, TB1 and TB2-specific antigens, and the production of IFN-γ was determined using the QuantiFERON-TB Gold Plus (QFT-Plus) test. The data were analyzed using SPSS 16 software and statistical significance was assessed at a two-tailed P value of 0.05. The median values of IFN-γ released following stimulation with TB1 peptides decreased slightly after treatment (2.5 IU/mL (IQR: 0.9-5.3), compared to the baseline (3.4 IU/mL (IQR: 0.5-6.6)). Also, with respect to the TB1 antigen, 38 out of 45 patients were positive for the QFT test before treatment (84.4%) and 37 cases after treatment (82.2%). On the other hand, the median values of IFN-γ determined with the TB2 test declined marginally after treatment (2.7 IU/mL; IQR: 0.95-5.8), as compared to pretreatment (3.0 IU/mL; IQR: 0.7-8.9). Thirty-nine out of 45 patients (86.7%) before initiation of treatment and 37 cases following a 3-month treatment (82.2%) were had positive values. Moreover, the median values of IFN-γ of TB2 minus TB1 before and after treatment were 0.17 (IQR: 0-1.0) and 0.03 (IQR: 0.0.48), respectively; however, these differences were not significant (p value=0.29). Conclusion: The results of this study show no significant differences between the IFN-γ release in TB patients prior to and after treatment. However, more extensive studies are needed in different populations with higher sample sizes to validate these results.

应用QuantiFERON-TB Gold Plus评价活动性肺结核的治疗效果。
结核病是世界范围内导致死亡的主要传染病之一,尽管最近在全球控制结核病方面取得了进展,但其发病率的下降仍然缓慢。因此,评估结核病治疗监测新工具的性能至关重要。本研究的目的是评估使用QuantiFERON-TB Gold Plus (QFT-Plus)试剂盒对结核病治疗的反应。对100名活动性结核病患者在治疗前和治疗成功且痰培养呈阴性的情况下三个月后采集血样。在存在或不存在TB抗原、TB1和tb2特异性抗原的情况下培养全血,使用QuantiFERON-TB Gold Plus (QFT-Plus)试验测定IFN-γ的产生。采用SPSS 16软件对数据进行分析,双侧P值为0.05。治疗后,TB1肽刺激后释放的IFN-γ的中位数(2.5 IU/mL (IQR: 0.9-5.3))与基线(3.4 IU/mL (IQR: 0.5-6.6))相比略有下降。在TB1抗原方面,45例患者治疗前QFT检测阳性38例(84.4%),治疗后37例(82.2%)。另一方面,治疗后用TB2试验测定的IFN-γ中位数略有下降(2.7 IU/mL;IQR: 0.95-5.8),与预处理(3.0 IU/mL;差:0.7 - -8.9)。45例患者治疗前阳性39例(86.7%),治疗3个月后阳性37例(82.2%)。TB2 - TB1治疗前后IFN-γ的中位数分别为0.17 (IQR: 0-1.0)和0.03 (IQR: 0.0.48);然而,这些差异不显著(p值=0.29)。结论:本研究结果显示结核患者治疗前后IFN-γ释放无显著差异。然而,需要在不同的人群中进行更广泛的研究,样本量更大,以验证这些结果。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
European cytokine network
European cytokine network 生物-免疫学
CiteScore
5.70
自引率
0.00%
发文量
5
审稿时长
6 months
期刊介绍: The journal that brings together all areas of work involving cytokines. European Cytokine Network is an electronic journal that publishes original articles and abstracts every quarter to provide an essential bridge between researchers and clinicians with an interest in this cutting-edge field. The journal has become a must-read for specialists in the field thanks to its swift publication and international circulation. The journal is referenced in several databases, including Medline, which is testament to its scientific quality.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信